Skip to content

Serotonergic antidepressant use is associated with weaker psilocybin effects

Natalie Gukasyan, Roland R. Griffiths, David B. Yaden, Denis Antoine, Sandeep M. Nayak

October 28, 2022 preprint DOI: 10.31234/osf.io/2zys9 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Online survey
Sample size 2,137
Population Individuals who used psilocybin with an antidepressant or within two years of discontinuing an antidepressant
Intervention Psilocybin
Topics Psilocybin Serotonin
Keywords Antidepressant Discontinuation Pharmacology Hallucinogen
Citations 1
Key findings Serotonergic antidepressants weaken psilocybin's effects relative to bupropion, and this dampening may last up to 3 months after discontinuation.

Abstract

Background: Psilocybin is being studied for depression, but little is known about how it interacts with common antidepressants. Limited data suggests that psilocybin’s effects may be diminished by serotonergic antidepressants acutely and even after a medication washout period.Aims: To learn the extent to which serotonergic antidepressants may diminish psilocybin’s effects both concurrently and after discontinuation of antidepressants.

Methods: Online survey of individuals with use of psilocybin 1) with an antidepressant and/or 2) within two years of discontinuing an antidepressant. Participants who took psilocybin with an antidepressant and either took the same dose of psilocybin pre-antidepressant or took the same dose with other people not on antidepressant reported the strength of psilocybin’s effect relative to their expectation. Participants who took psilocybin following discontinuation of a serotonergic antidepressant also reported the presence of weakened effects.

Results: In reports (n=595) of taking psilocybin with an antidepressant, probabilities [95% CI] of weaker than expected psilocybin effects were 0.48 [0.41-0.54] (SSRIs), 0.56 [0.44-0.67] (SNRIs) and 0.29 [0.2-0.39] (bupropion). Following serotonergic antidepressant discontinuation (n=1,542 reports), the odds of reduced psilocybin effects were not significantly different from the earliest post-discontinuation timepoint (within 1 week) until 3-6 months OR = 0.42, 95% [0.25-0.72] p = 0.001.Conclusions: Serotonergic antidepressants appear to weaken psilocybin’s effects relative to a non-serotonergic antidepressant. This dampening effect on psilocybin effects may last as long as 3 months following antidepressant discontinuation.

Comparable studies

Other cross-sectional and survey studies on serotonin, most cited first.

Study Year Design Participants
Reducedin vivobinding to the serotonin transporter in the cerebral cortex of MDMA (‘ecstasy’) users Male regular ecstasy users and well-matched controls 1999 Cross-sectional association study n = 20
Cerebral1H MRS alterations in recreational 3,4-methylenedioxymethamphetamine (MDMA, ?ecstasy?) users Recreational MDMA users and normal subjects 1999 Cross-sectional study n = 59
Evidence for a common biological basis of the absorption trait, hallucinogen effects, and positive symptoms: Epistasis between 5-HT2a and COMT polymorphisms 95 male and 241 female subjects 2005 Cross-sectional genetic association study n = 336
Recreational use of psychedelics is associated with elevated personality trait openness: Exploration of associations with brain serotonin markers. 10 psychedelic-preferring recreational users, 14 MDMA-preferring users, and 21... 2019 Cross-sectional observational study n = 45
In Vivo Imaging of Cerebral Serotonin Transporter and Serotonin2A Receptor Binding in 3,4-Methylenedioxymethamphetamine (MDMA or “Ecstasy”) and Hallucinogen Users 2011 Cross-sectional study

Citations in the library

Explore topics